APO Research
Talk to an analyst

APO RESEARCH · REPORT

Transdermal Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Transdermal Drug Market Outlook and Growth Opportunities 2026

26 December 2025209 pages

Choose your research edition.

Industry ResearchTransdermal Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Transdermal Drug Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Transdermal Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transdermal Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Transdermal Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Transdermal Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Transdermal Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Transdermal Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Transdermal Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Transdermal Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Transdermal Drug market include Johnson & Johnson, Novartis, Mylan, GSK, Beijing Tide Pharmaceutical, Bayer, UCB Pharma, Teva Pharmaceutical and Nitto Denko, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Transdermal Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Transdermal Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Transdermal Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Transdermal Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Transdermal Drug Segment by Company

Johnson & Johnson

Novartis

Mylan

GSK

Beijing Tide Pharmaceutical

Bayer

UCB Pharma

Teva Pharmaceutical

Nitto Denko

Mundipharma

Luye Pharma Group

IBSA Group

Hisamitsu Pharmaceutical

Grünenthal

Dr Reddy’s Laboratories

Chattem

Transdermal Drug Segment by Type

Methyl Salicylate-based Patch

Diclofenac Patch

Nicotine Transdermal Patch

Lidocaine Patch

Rivastigmine Transdermal Patch

Fentanyl Transdermal Patch

Others

Transdermal Drug Segment by Application

Rx Channel

OTC Channel

Transdermal Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Transdermal Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Transdermal Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Transdermal Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Transdermal Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transdermal Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transdermal Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transdermal Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Transdermal Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transdermal Drug industry.

Chapter 3: Detailed analysis of Transdermal Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Transdermal Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Transdermal Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Transdermal Drug Industry Trends Table 2. Transdermal Drug Industry Drivers Table 3. Transdermal Drug Industry Opportunities and Challenges Table 4. Transdermal Drug Industry Restraints Table 5. Global Transdermal Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Transdermal Drug Revenue Share by Company (2021-2026) Table 7. Global Transdermal Drug Sales Volume by Company (M Pcs) & (2021-2026) Table 8. Global Transdermal Drug Sales Volume Share by Company (2021-2026) Table 9. Global Transdermal Drug Average Price (US$/Pcs) of Company (2021-2026) Table 10. Global Transdermal Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Transdermal Drug Key Company Manufacturing Base & Headquarters Table 12. Global Transdermal Drug Company, Product Type & Application Table 13. Global Transdermal Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Transdermal Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Methyl Salicylate-based Patch Table 18. Significant Companies of Diclofenac Patch Table 19. Significant Companies of Nicotine Transdermal Patch Table 20. Significant Companies of Lidocaine Patch Table 21. Significant Companies of Rivastigmine Transdermal Patch Table 22. Significant Companies of Fentanyl Transdermal Patch Table 23. Significant Companies of Others Table 24. Global Transdermal Drug Sales Volume by Type 2021 VS 2025 VS 2032 (M Pcs) Table 25. Global Transdermal Drug Sales Volume by Type (2021-2026) & (M Pcs) Table 26. Global Transdermal Drug Sales Volume by Type (2027-2032) & (M Pcs) Table 27. Global Transdermal Drug Sales Volume Share by Type (2021-2026) Table 28. Global Transdermal Drug Sales Volume Share by Type (2027-2032) Table 29. Global Transdermal Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Transdermal Drug Sales Value by Type (2021-2026) & (US$ Million) Table 31. Global Transdermal Drug Sales Value by Type (2027-2032) & (US$ Million) Table 32. Global Transdermal Drug Sales Value Share by Type (2021-2026) Table 33. Global Transdermal Drug Sales Value Share by Type (2027-2032) Table 34. Significant Companies of Rx Channel Table 35. Significant Companies of OTC Channel Table 36. Global Transdermal Drug Sales Volume by Application 2021 VS 2025 VS 2032 (M Pcs) Table 37. Global Transdermal Drug Sales Volume by Application (2021-2026) & (M Pcs) Table 38. Global Transdermal Drug Sales Volume by Application (2027-2032) & (M Pcs) Table 39. Global Transdermal Drug Sales Volume Share by Application (2021-2026) Table 40. Global Transdermal Drug Sales Volume Share by Application (2027-2032) Table 41. Global Transdermal Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Transdermal Drug Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Transdermal Drug Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Transdermal Drug Sales Value Share by Application (2021-2026) Table 45. Global Transdermal Drug Sales Value Share by Application (2027-2032) Table 46. Global Transdermal Drug Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Table 47. Global Transdermal Drug Sales by Region (2021-2026) & (M Pcs) Table 48. Global Transdermal Drug Sales Market Share by Region (2021-2026) Table 49. Global Transdermal Drug Sales by Region (2027-2032) & (M Pcs) Table 50. Global Transdermal Drug Sales Market Share by Region (2027-2032) Table 51. Global Transdermal Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Transdermal Drug Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Transdermal Drug Sales Value Share by Region (2021-2026) Table 54. Global Transdermal Drug Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Transdermal Drug Sales Value Share by Region (2027-2032) Table 56. Global Transdermal Drug Market Average Price (US$/Pcs) by Region (2021-2026) Table 57. Global Transdermal Drug Market Average Price (US$/Pcs) by Region (2027-2032) Table 58. Global Transdermal Drug Sales by Country: 2021 VS 2025 VS 2032 (M Pcs) Table 59. Global Transdermal Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Transdermal Drug Sales by Country (2021-2026) & (M Pcs) Table 61. Global Transdermal Drug Sales Market Share by Country (2021-2026) Table 62. Global Transdermal Drug Sales by Country (2027-2032) & (M Pcs) Table 63. Global Transdermal Drug Sales Market Share by Country (2027-2032) Table 64. Global Transdermal Drug Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Transdermal Drug Sales Value Market Share by Country (2021-2026) Table 66. Global Transdermal Drug Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Transdermal Drug Sales Value Market Share by Country (2027-2032) Table 68. Johnson & Johnson Company Information Table 69. Johnson & Johnson Business Overview Table 70. Johnson & Johnson Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 71. Johnson & Johnson Transdermal Drug Product Portfolio Table 72. Johnson & Johnson Recent Development Table 73. Novartis Company Information Table 74. Novartis Business Overview Table 75. Novartis Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 76. Novartis Transdermal Drug Product Portfolio Table 77. Novartis Recent Development Table 78. Mylan Company Information Table 79. Mylan Business Overview Table 80. Mylan Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 81. Mylan Transdermal Drug Product Portfolio Table 82. Mylan Recent Development Table 83. GSK Company Information Table 84. GSK Business Overview Table 85. GSK Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 86. GSK Transdermal Drug Product Portfolio Table 87. GSK Recent Development Table 88. Beijing Tide Pharmaceutical Company Information Table 89. Beijing Tide Pharmaceutical Business Overview Table 90. Beijing Tide Pharmaceutical Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 91. Beijing Tide Pharmaceutical Transdermal Drug Product Portfolio Table 92. Beijing Tide Pharmaceutical Recent Development Table 93. Bayer Company Information Table 94. Bayer Business Overview Table 95. Bayer Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 96. Bayer Transdermal Drug Product Portfolio Table 97. Bayer Recent Development Table 98. UCB Pharma Company Information Table 99. UCB Pharma Business Overview Table 100. UCB Pharma Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 101. UCB Pharma Transdermal Drug Product Portfolio Table 102. UCB Pharma Recent Development Table 103. Teva Pharmaceutical Company Information Table 104. Teva Pharmaceutical Business Overview Table 105. Teva Pharmaceutical Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 106. Teva Pharmaceutical Transdermal Drug Product Portfolio Table 107. Teva Pharmaceutical Recent Development Table 108. Nitto Denko Company Information Table 109. Nitto Denko Business Overview Table 110. Nitto Denko Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 111. Nitto Denko Transdermal Drug Product Portfolio Table 112. Nitto Denko Recent Development Table 113. Mundipharma Company Information Table 114. Mundipharma Business Overview Table 115. Mundipharma Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 116. Mundipharma Transdermal Drug Product Portfolio Table 117. Mundipharma Recent Development Table 118. Luye Pharma Group Company Information Table 119. Luye Pharma Group Business Overview Table 120. Luye Pharma Group Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 121. Luye Pharma Group Transdermal Drug Product Portfolio Table 122. Luye Pharma Group Recent Development Table 123. IBSA Group Company Information Table 124. IBSA Group Business Overview Table 125. IBSA Group Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 126. IBSA Group Transdermal Drug Product Portfolio Table 127. IBSA Group Recent Development Table 128. Hisamitsu Pharmaceutical Company Information Table 129. Hisamitsu Pharmaceutical Business Overview Table 130. Hisamitsu Pharmaceutical Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 131. Hisamitsu Pharmaceutical Transdermal Drug Product Portfolio Table 132. Hisamitsu Pharmaceutical Recent Development Table 133. Grünenthal Company Information Table 134. Grünenthal Business Overview Table 135. Grünenthal Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 136. Grünenthal Transdermal Drug Product Portfolio Table 137. Grünenthal Recent Development Table 138. Dr Reddy’s Laboratories Company Information Table 139. Dr Reddy’s Laboratories Business Overview Table 140. Dr Reddy’s Laboratories Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 141. Dr Reddy’s Laboratories Transdermal Drug Product Portfolio Table 142. Dr Reddy’s Laboratories Recent Development Table 143. Chattem Company Information Table 144. Chattem Business Overview Table 145. Chattem Transdermal Drug Sales (M Pcs), Value (US$ Million), Price (US$/Pcs) and Gross Margin (2021-2026) Table 146. Chattem Transdermal Drug Product Portfolio Table 147. Chattem Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Transdermal Drug Distributors List Table 151. Transdermal Drug Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Transdermal Drug Product Image Figure 2. Global Transdermal Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transdermal Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Transdermal Drug Sales (2021-2032) & (M Pcs) Figure 5. Global Transdermal Drug Sales Average Price (US$/Pcs) & (2021-2032) Figure 6. Global Transdermal Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Methyl Salicylate-based Patch Image Figure 10. Diclofenac Patch Image Figure 11. Nicotine Transdermal Patch Image Figure 12. Lidocaine Patch Image Figure 13. Rivastigmine Transdermal Patch Image Figure 14. Fentanyl Transdermal Patch Image Figure 15. Others Image Figure 16. Global Transdermal Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (M Pcs) Figure 17. Global Transdermal Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 18. Global Transdermal Drug Sales Volume Share by Type (2021-2032) Figure 19. Global Transdermal Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Transdermal Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Transdermal Drug Sales Value Share by Type (2021-2032) Figure 22. Rx Channel Image Figure 23. OTC Channel Image Figure 24. Global Transdermal Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (M Pcs) Figure 25. Global Transdermal Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Transdermal Drug Sales Volume Share by Application (2021-2032) Figure 27. Global Transdermal Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Transdermal Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Transdermal Drug Sales Value Share by Application (2021-2032) Figure 30. Global Transdermal Drug Sales by Region: 2021 VS 2025 VS 2032 (M Pcs) Figure 31. Global Transdermal Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Transdermal Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Transdermal Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Transdermal Drug Sales Value (2021-2032) & (US$ Million) Figure 35. North America Transdermal Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Transdermal Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Transdermal Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Transdermal Drug Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Transdermal Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Transdermal Drug Sales Value (2021-2032) & (US$ Million) Figure 41. South America Transdermal Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Transdermal Drug Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Transdermal Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Transdermal Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Transdermal Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Transdermal Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Transdermal Drug Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Transdermal Drug Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Methyl Salicylate-based Patch
  • Diclofenac Patch
  • Nicotine Transdermal Patch
  • Lidocaine Patch
  • Rivastigmine Transdermal Patch
  • Fentanyl Transdermal Patch
  • Others
Applications
  • Rx Channel
  • OTC Channel
Companies covered
  • Johnson & Johnson
  • Novartis
  • Mylan
  • GSK
  • Beijing Tide Pharmaceutical
  • Bayer
  • UCB Pharma
  • Teva Pharmaceutical
  • Nitto Denko
  • Mundipharma
  • Luye Pharma Group
  • IBSA Group
  • Hisamitsu Pharmaceutical
  • Grünenthal
  • Dr Reddy’s Laboratories
  • Chattem

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Transdermal Drug Sales Value (2021-2032)
  4. 1.2.2 Global Transdermal Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Transdermal Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Transdermal Drug Market Dynamics
  1. 2.1 Transdermal Drug Industry Trends
  2. 2.2 Transdermal Drug Industry Drivers
  3. 2.3 Transdermal Drug Industry Opportunities and Challenges
  4. 2.4 Transdermal Drug Industry Restraints
3 Transdermal Drug Market by Company
  1. 3.1 Global Transdermal Drug Company Revenue Ranking in 2025
  2. 3.2 Global Transdermal Drug Revenue by Company (2021-2026)
  3. 3.3 Global Transdermal Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Transdermal Drug Average Price by Company (2021-2026)
  5. 3.5 Global Transdermal Drug Company Ranking (2024-2026)
  6. 3.6 Global Transdermal Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Transdermal Drug Company Product Type and Application
  8. 3.8 Global Transdermal Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Transdermal Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Transdermal Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Transdermal Drug Market by Type
  1. 4.1 Transdermal Drug Type Introduction
  2. 4.1.1 Methyl Salicylate-based Patch
  3. 4.1.2 Diclofenac Patch
  4. 4.1.3 Nicotine Transdermal Patch
  5. 4.1.4 Lidocaine Patch
  6. 4.1.5 Rivastigmine Transdermal Patch
  7. 4.1.6 Fentanyl Transdermal Patch
  8. 4.1.7 Others
  9. 4.2 Global Transdermal Drug Sales Volume by Type
  10. 4.2.1 Global Transdermal Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Transdermal Drug Sales Volume by Type (2021-2032)
  12. 4.2.3 Global Transdermal Drug Sales Volume Share by Type (2021-2032)
  13. 4.3 Global Transdermal Drug Sales Value by Type
  14. 4.3.1 Global Transdermal Drug Sales Value by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Transdermal Drug Sales Value by Type (2021-2032)
  16. 4.3.3 Global Transdermal Drug Sales Value Share by Type (2021-2032)
5 Transdermal Drug Market by Application
  1. 5.1 Transdermal Drug Application Introduction
  2. 5.1.1 Rx Channel
  3. 5.1.2 OTC Channel
  4. 5.2 Global Transdermal Drug Sales Volume by Application
  5. 5.2.1 Global Transdermal Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Transdermal Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Transdermal Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Transdermal Drug Sales Value by Application
  9. 5.3.1 Global Transdermal Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Transdermal Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Transdermal Drug Sales Value Share by Application (2021-2032)
6 Transdermal Drug Regional Sales and Value Analysis
  1. 6.1 Global Transdermal Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Transdermal Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Transdermal Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Transdermal Drug Sales by Region (2027-2032)
  5. 6.3 Global Transdermal Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Transdermal Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Transdermal Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Transdermal Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Transdermal Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Transdermal Drug Sales Value (2021-2032)
  12. 6.6.2 North America Transdermal Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Transdermal Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Transdermal Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Transdermal Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Transdermal Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Transdermal Drug Sales Value (2021-2032)
  21. 6.9.2 South America Transdermal Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Transdermal Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Transdermal Drug Sales Value Share by Country, 2025 VS 2032
7 Transdermal Drug Country-level Sales and Value Analysis
  1. 7.1 Global Transdermal Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Transdermal Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Transdermal Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Transdermal Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Transdermal Drug Sales by Country (2027-2032)
  6. 7.4 Global Transdermal Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Transdermal Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Transdermal Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Transdermal Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Transdermal Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Transdermal Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Transdermal Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Transdermal Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Transdermal Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Transdermal Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Transdermal Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Transdermal Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Transdermal Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Transdermal Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Transdermal Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Transdermal Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Transdermal Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Transdermal Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Transdermal Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Transdermal Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Transdermal Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Transdermal Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Transdermal Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Transdermal Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Transdermal Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Transdermal Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Transdermal Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Transdermal Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Transdermal Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Transdermal Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Transdermal Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Transdermal Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Transdermal Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Transdermal Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Transdermal Drug Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Transdermal Drug Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Mylan
  14. 8.3.1 Mylan Company Information
  15. 8.3.2 Mylan Business Overview
  16. 8.3.3 Mylan Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Transdermal Drug Product Portfolio
  18. 8.3.5 Mylan Recent Developments
  19. 8.4 GSK
  20. 8.4.1 GSK Company Information
  21. 8.4.2 GSK Business Overview
  22. 8.4.3 GSK Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GSK Transdermal Drug Product Portfolio
  24. 8.4.5 GSK Recent Developments
  25. 8.5 Beijing Tide Pharmaceutical
  26. 8.5.1 Beijing Tide Pharmaceutical Company Information
  27. 8.5.2 Beijing Tide Pharmaceutical Business Overview
  28. 8.5.3 Beijing Tide Pharmaceutical Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Beijing Tide Pharmaceutical Transdermal Drug Product Portfolio
  30. 8.5.5 Beijing Tide Pharmaceutical Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Transdermal Drug Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 UCB Pharma
  38. 8.7.1 UCB Pharma Company Information
  39. 8.7.2 UCB Pharma Business Overview
  40. 8.7.3 UCB Pharma Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 UCB Pharma Transdermal Drug Product Portfolio
  42. 8.7.5 UCB Pharma Recent Developments
  43. 8.8 Teva Pharmaceutical
  44. 8.8.1 Teva Pharmaceutical Company Information
  45. 8.8.2 Teva Pharmaceutical Business Overview
  46. 8.8.3 Teva Pharmaceutical Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Teva Pharmaceutical Transdermal Drug Product Portfolio
  48. 8.8.5 Teva Pharmaceutical Recent Developments
  49. 8.9 Nitto Denko
  50. 8.9.1 Nitto Denko Company Information
  51. 8.9.2 Nitto Denko Business Overview
  52. 8.9.3 Nitto Denko Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Nitto Denko Transdermal Drug Product Portfolio
  54. 8.9.5 Nitto Denko Recent Developments
  55. 8.10 Mundipharma
  56. 8.10.1 Mundipharma Company Information
  57. 8.10.2 Mundipharma Business Overview
  58. 8.10.3 Mundipharma Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Mundipharma Transdermal Drug Product Portfolio
  60. 8.10.5 Mundipharma Recent Developments
  61. 8.11 Luye Pharma Group
  62. 8.11.1 Luye Pharma Group Company Information
  63. 8.11.2 Luye Pharma Group Business Overview
  64. 8.11.3 Luye Pharma Group Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Luye Pharma Group Transdermal Drug Product Portfolio
  66. 8.11.5 Luye Pharma Group Recent Developments
  67. 8.12 IBSA Group
  68. 8.12.1 IBSA Group Company Information
  69. 8.12.2 IBSA Group Business Overview
  70. 8.12.3 IBSA Group Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 IBSA Group Transdermal Drug Product Portfolio
  72. 8.12.5 IBSA Group Recent Developments
  73. 8.13 Hisamitsu Pharmaceutical
  74. 8.13.1 Hisamitsu Pharmaceutical Company Information
  75. 8.13.2 Hisamitsu Pharmaceutical Business Overview
  76. 8.13.3 Hisamitsu Pharmaceutical Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Hisamitsu Pharmaceutical Transdermal Drug Product Portfolio
  78. 8.13.5 Hisamitsu Pharmaceutical Recent Developments
  79. 8.14 Grünenthal
  80. 8.14.1 Grünenthal Company Information
  81. 8.14.2 Grünenthal Business Overview
  82. 8.14.3 Grünenthal Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Grünenthal Transdermal Drug Product Portfolio
  84. 8.14.5 Grünenthal Recent Developments
  85. 8.15 Dr Reddy’s Laboratories
  86. 8.15.1 Dr Reddy’s Laboratories Company Information
  87. 8.15.2 Dr Reddy’s Laboratories Business Overview
  88. 8.15.3 Dr Reddy’s Laboratories Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Dr Reddy’s Laboratories Transdermal Drug Product Portfolio
  90. 8.15.5 Dr Reddy’s Laboratories Recent Developments
  91. 8.16 Chattem
  92. 8.16.1 Chattem Company Information
  93. 8.16.2 Chattem Business Overview
  94. 8.16.3 Chattem Transdermal Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Chattem Transdermal Drug Product Portfolio
  96. 8.16.5 Chattem Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Transdermal Drug Value Chain Analysis
  2. 9.1.1 Transdermal Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Transdermal Drug Sales Mode & Process
  6. 9.2 Transdermal Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Transdermal Drug Distributors
  9. 9.2.3 Transdermal Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst